Russia has reported that its cancer vaccine "Enteromix" has completed preclinical trials—demonstrating both safety and high efficacy.

Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), made the announcement on Saturday at the Eastern Economic Forum (EEF) in Vladivostok, according to a report by Russian news agency TASS.

"The research spanned several years, with the last three dedicated to mandatory preclinical studies," Skvortsova reportedly said. "The vaccine is now ready for use; we are awaiting official approval."

Skvortsova is said to have emphasized that preclinical results confirmed the vaccine's safety, even with repeated administration, and significant effectiveness.

Researchers observed reductions in tumor size and slowed tumor progression—rangi

See Full Page